FindTrial
Sign In

interferon alpha 2b

DRUG4 trials

Sponsors

University of Alberta, M.D. Anderson Cancer Center, Laboratorio Pablo Cassará S.R.L., Junqi Niu

Conditions

BurnCutaneous MelanomaHepatitis C, ChronicHypertrophic ScarInterferon DeficiencyLiver DiseasesMelanoma

Phase 1

Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma
CompletedNCT00970996
M.D. Anderson Cancer CenterMelanoma
Start: 2009-09-30End: 2012-12-31Updated: 2013-01-03

Phase 2

Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients
NCT01729663
Laboratorio Pablo Cassará S.R.L.Cutaneous Melanoma
Start: 2009-04-30Target: 108Updated: 2015-09-02

Phase 3

Intron A for the Treatment of Hypertrophic Scar
WithdrawnNCT00686478
University of AlbertaBurn, Hypertrophic Scar
Updated: 2014-01-30

Unknown Phase

Patterns of Early Hepatitis C Virus Decline Predict the Outcome of Interferon Therapy (sIFN-pred2)
NCT01760148
Junqi NiuHepatitis C, Chronic, Interferon Deficiency, Liver Diseases
Start: 2012-07-31End: 2014-03-31Target: 300Updated: 2013-01-04

Related Papers

Changes in the TCRβ Repertoire and Tumor Immune Signature From a Cutaneous Melanoma Patient Immunized With the CSF-470 Vaccine: A Case Report
Frontiers in Immunology2018-05-0316 citations
Abstract 3677: Early effects of CSF-470 melanoma vaccine plus adjuvants in immune cell stimulation
Cancer Research2017-07-01
Phase II Study of Adjuvant Immunotherapy with the CSF-470 Vaccine Plus Bacillus Calmette–Guerin Plus Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor vs Medium-Dose Interferon Alpha 2B in Stages IIB, IIC, and III Cutaneous Melanoma Patients: A Single Institution, Randomized Study
Frontiers in Immunology2017-05-3129 citations
Abstract 4897: First evidence of changes in the TCRâ repertoire from a cutaneous melanoma patient immunized with the CSF-470 vaccine
Cancer Research2016-07-15
Abstract A50: Immunomonitoring in a phase II/III trial of therapeutic vaccination with CSF-470 plus BCG plus GM-CSF versus IFN-alfa in patients with cutaneous melanoma
Cancer Immunology Research2015-10-012 citations
Abstract A37: Immunization of cutaneous melanoma patients with the allogeneic cell vaccine CSF-470 enhances immune infiltration of metastatic lesions and would favor subsequent response to Vemurafenib
Cancer Immunology Research2015-10-011 citations
Abstract CT118: A randomized phase II study of the CSF-470 therapeutic vaccine plus BCG plus rhGM-CSF versus IFN-α2b in cutaneous melanoma patients stages IIB, IIC and III
Cancer Research2015-08-011 citations